PATENT 4518-0108PUS1

IN THE U.S. PATENT AND TRADEMARK OFFICE

LOIBNER, Hans et al.

Conf.:

3426

Appl. No.:

10/524,520

Group:

1645

Filed:

February 11, 2005

Examiner: UNKNOWN

For:

USE OF ANTIBODIES AGAINST TUMOR-

ASSOCIATED ANTIGEN

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER FILING OF AN APPLICATION BUT BEFORE FINAL REJECTION OR NOTICE OF ALLOWANCE OR CONCURRENTLY WITH A RULE 1.114 RCE APPLICATION)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450 August 18, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449(s), attached hereto.

- II. COPIES (check at least one box)
 - CD-Rom is attached which contains a. 冈 copies of all references listed on the attached PTO-1449 Form, including U.S. patents.
 - b. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

a. DOCUMENTS IN THE ENGLISH LANGUAGE

The patents, publications, or other information listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:


c. ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. OTHER


The following additional information is provided for the Examiner's consideration.

FEES



VI. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that



- b.
 each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. Some of the items of information were cited in a communication from a foreign Patent Office. As to information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Office in a counterpart application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VII.	PAYME	ENT OF FE	EES (check one box)
			in the amount of $\frac{$180.00}{1.17}$ as required by 37 1.17 (p) is enclosed for the above-identified
		amount 1	charge Deposit Account No. 02-2448 in the required by 37 C.F.R. § 1.17(p) for the aboveded fee. This paper is submitted in triplicate.
	\boxtimes	No fee i	is required.
the A and c this, credi addit	ne is rmined PTO is charge If n con t an	reques that t reques the app ecessary current, y overpa fees re	iner has any questions concerning this IDS, sted to contact the undersigned. If it is this IDS has been filed under the wrong rule, ted to consider this IDS under the proper rule propriate fee to Deposit Account No. 02-2448. To the Commissioner is hereby authorized in and future replies, to charge payment or anyment to Deposit Account No. 02-2448 for any equired under 37 C.F.R. § 1.16 or under § 1.17; tension of time fees.
I hereby certify posited with the class mail, po Commissioner f VA 22313-1450	e United ostage proof Patents), on:	States Postal S epaid, in an i, P.O. Box 145 (Date of Dep	Respectfully submitted, envelope to: 60, Alexandria, Positi) Respectfully submitted, Respectfully submitted, FOR A STEWART, KOLASCH & BIRCH, LLP
BIRCH, STEV	VARŤ, K	COLASCH &	BY
LRS/1 4518-	.mt 9	gnature) ugust (Storing)	Leonard R. Svensson, #30,330 P.O. Box 747 Falls Church, VA 22040-0747 (714) 708-8555
Attac	hment	(s): 🖂	PTO-1449
			Documents
			Foreign Search Report
		. \square	Fee
		\boxtimes	Other: CD-Rom containing references listed on PTO-1449 Form

orm P	TO-1449			ATTY. DOCKET NO. 4518-0108PUS1		APPLICATI 10/52)	
נ		TION DISCL IN AN APPL	APPLICANT LOIBNER, Hans et al.						
	(Use several sheets if necessary)				FILING DATE February 11, 2	2005	GROUP		
			Ū	.S. PATENT I			<u> </u>		
EXAMINER INITIAL	DOCUM	MENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILII IF APP	NG DATE
	119 20	001/0006618	A1	2001-07-05	Goldenberg				
-		4,643,971	N	1987-02-17	Frader et al.		ļ		
	J			1307-02-17	riauei et ai.		ļ <u>-</u>		
	US		1					-	
			1		 	-	,		
	US US US US US US								
			-			1			
								 	
							<u> </u>	 	
	U	S .				+			
			FOR	EIGN PATENT	DOCUMENTS		 	<u> </u>	
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANS	SLATION
	WO	01/23005	A1	2001-04-05	WIPO			163	+-
	WO	00/69460	A1.	2000-11-23	WIPO			-	+
	WO	01/03738	A1	2001-01-18	WIPO				\vdash
	WO	93/21940	A1	1993-11-11	WIPO				+
	EP	1140168	B1	2002-06-26	EPO				
							1		1
									1
				. "					
THE	R DOCUM	ENTS (Include Na	me of the auth	or (in CAPITAL LETTERS),	title of the article (when appr isher, city and/or country when	opriate), tit	cle of the it	em (book,	magazin
	(Abstra	act)Swayne L.	C. et al	. " SPECT anti-	CEA monoclonal ant article, Vol. 16, N	ibody d	etection November	n of o	ccul

(Abstract) Cote R.J. et al. " Intraoperative monoclonal antibody CC49" Journal Article, Vol. 77, No. 4, February 15,1996, pp.613-620 (Abstract)Lechner P. et al. "Tc-99m-labeled anti-CEA antibodies in intraoperative diagnosis of colorectal cancer"Journal Article, Vol. 34, No. 1, February 1995, pp.8-

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

m PTO-1449	ATTY. DOCKET NO. 4518-0108PUS1	APPLICATION NO.		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT LOIBNER, Hans et al.			
(Use several sheets if necessary)	Filing DATE February 11,2005	GROUP		

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published. J.P. Chippaux and M. Goyffon. "Venoms, Antivenoms and Immunotherapy" Journal Toxicon, Vol.36, No.6, May 7,1997, pp. 823-846 G. Riethmüller. et.al. "Monoclonal Antibody Therapy for Resected Dukes' C Colorectal Cancer: Seven-Year Outcome of a Multicenter Randomized Trial" Journal of Clinical Oncology, Vol.16, No.5, May 1998, pp.1788-1794 Tatsuaki, Nakashio et al. " Peritoneal dissemination is inhibited by treatment with antibodies against CD44H, B1 integrin, carcinostatic agents in NUGC-4 human gastric cancer cells" International Journal of Oncology, Vol. 10, 1997, pp.355-362 Barchi, Joseph J. Jr. " Emerging Roles of Carbohydrates and Glycomimetics in Anticancer Drug Design" Current Pharmaceutical Design, Vol. 6,2000,pp.485-501 Ben-Yedidia Tamar and Arnon Ruth." Design of Peptide and Polypeptide vaccines" Biotechnology, Vol.8, 1997, pp.442-448 Casadevall, Arturo and Scharff, Matthew D. " Return to the Past: The Case for Antibody-Based Therapies in Infectious Diseases" Clinical Infectious Diseases, Vol.21,1995,pp.150-161 Glennie, Martin J. and Johnson, Peter W.M. "Clinical trials of antibody therapy" Journal Immunology Today, Vol.21, no. 8, August 2000, pp.403-410 Gollogly, V. Castronovo. " A possible role for the alpha $1\rightarrow 3$ galactosyl epitope and natural anti-gal antibody in ontogenesis" Neoplasma Journal, Vol.43, No.5, 1996, pp.285- 289 Herlyn, Dorothy and Birebent Brigitte. " Advances in cancer vaccine development" the Finnish Medical Society Duodecim, Vol. 31, 1999, pp. 66-78 Lewis, Jonathan J. and Houghton, Alan N. " Definition of tumor antigens suitable for vaccine construction" Cancer Biology, Vol.6,1995,pp.321-327 Melief, Cornelis J.M. et al. " Peptide-based cancer vaccines" Current Opinion in Immunology, Vol. 8, 1996, pp. 651-657 Miyake, Masayuki. et. al. "Correlation of Expression of H/Ley/Leb Antigens with Survival in Patients with Carcinoma of the Lung" The New England Journal of Medicine, July 2, 1992,pp.14-18 Orntoft, F. Torben and Vestergaard, Else Marie. "Clinical aspects of altered glycosylation of glycoproteins in cancer" Electrophoresis Journal, Vol.20, 1999, pp.362-371 Scott, Andrew M. and Welt, Sydney. "Antibody-based immunological therapies" Journal of Current Opinion on Immunology, Vol. 9. 1997, pp.717-722 Weitz, Jurgen MD and Herfarath, Christian MD. "Surgical Strategies and Minimal Residual Disease Detection" Seminars in Surgical Oncology, Vol.20, 2001, pp.329-333 EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.